Testing abexinostat with low-dose Temodar for glioma that has come back
Original title: A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people to find a safe dose and learn about side effects.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests a new drug called abexinostat together with the chemo pill temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary for brain tumors that have come back.
Who this trial is for. This trial is for adults whose glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary came back after radiation and chemo. That includes glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary and some other gliomas. It tests abexinostat with temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary, also called Temodar, taken in low doses on a steady schedule.
Where it stands. The trial is looking for the right dose of abexinostat to use with temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary. It is also looking at what side effects happen. The trial has not reported results yet.
What this means, and what it doesn't
What it could mean: glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary that comes back has few treatment choices, so researchers are testing new mixes of drugs. If you or someone you care for has glioma that came back, you could ask the care team about this trial. The trial team decides who can join.
What it doesn't mean: This trial is a test, not a proven treatment. Joining it does not promise that it will help. It is not a cure. This first step is mostly about finding a safe dose and learning about side effects.
Source: ClinicalTrials.gov, September 14, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.